BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
BridgeBio Pharma (BBIO) will present acoramidis and ATTR-CM research at the American Heart Association Scientific Sessions on November 6–9, 2026. The Chicago meeting will feature two moderated posters, three posters and one Abbott Laboratories-led, BridgeBio-supported poster.
Presentations include analyses from ATTRibute-CM examining heart failure events, repeated cardiovascular hospitalizations and mortality, and recovery after cardiovascular hospitalization. Other presentations address screening and detection of transthyretin amyloid cardiomyopathy (ATTR-CM) and laboratory detection of transthyretin. No numerical findings from these presentations are disclosed.
BridgeBio Pharma (BBIO) reported third-quarter 2026 revenue of $353.2 million, alongside Attruby sales growth and updates on three pending drug applications. U.S. Attruby net product revenue reached $253.2 million, up approximately $31 million sequentially and $145 million year over year. Operating loss was $11.6 million; results included a one-time $75.0 million BEYONTTRA sales milestone from Bayer. Cash, cash equivalents and marketable securities totaled $1.5 billion at September 30.
FDA decision dates are November 27, 2026 for BBP-418, February 4, 2027 for oral infigratinib and May 8, 2027 for encaleret, all with Priority Review. European applications for infigratinib and encaleret are under review. BridgeBio reported additional clinical findings across its programs and dosed the first participants in studies testing acoramidis for potential cardiac disease reversal and encaleret for chronic hypoparathyroidism.
BridgeBio Pharma (Nasdaq: BBIO) will release its third quarter 2026 financial results after market close on October 29, 2026. The company will host a conference call at 4:30 pm ET that day to discuss its financial results and program updates. A webcast replay will remain available on its website for 30 days following the event.
BridgeBio Pharma (BBIO) approved restricted stock unit grants covering 57,853 common shares on October 14, 2026, as inducements for new employees.
The compensation committee approved the awards for 32 new employees under Nasdaq Listing Rule 5635(c)(4). Restricted stock units are awards tied to company shares that vest over time. One-fourth of each employee’s underlying shares will vest on November 16, 2027, followed by one-twelfth of the remaining shares each quarter. Each installment requires continued employment with BridgeBio or a subsidiary on the vesting date.
BridgeBio Pharma (BBIO) announced independent real-world findings associating acoramidis with an 18% lower risk of a composite clinical outcome versus tafamidis.
The matched electronic health record study included 2,684 people with transthyretin amyloid cardiomyopathy (ATTR-CM). The composite covered death, all-cause hospitalization, new-onset atrial fibrillation and increased diuretic treatment (p<0.01). Acoramidis was associated with 27% lower cardiovascular hospitalization risk, 27% lower heart failure hospitalization risk and 25% lower all-cause hospitalization risk (all p<0.001). Death and new-onset atrial fibrillation differences were not statistically significant. Residual confounding cannot be excluded, follow-up was relatively short and full results remain under peer review. Phase 3 analyses presented at HFSA also reported hospitalization and quality-of-life benefits versus placebo.
BridgeBio Pharma (Nasdaq: BBIO) presented Phase 3 CALIBRATE results showing encaleret improved reported symptoms and increased bone turnover in ADH1.
All encaleret participants reported improvement in at least one symptom, versus 46% receiving standard care. At 24 weeks, parathyroid hormone, which regulates calcium, reached at least the lower normal limit in 91% versus 0%. Bone formation and breakdown markers increased versus conventional therapy; reported daily-function improvements were also more frequent with encaleret.
The FDA accepted the ADH1 approval application and granted Priority Review, with a May 8, 2027 target action date. BridgeBio also submitted a European approval application. The first participant received encaleret in RECLAIM-HP, a Phase 3 chronic hypoparathyroidism study planned to enroll approximately 160 adults and adolescents.
BridgeBio Pharma (BBIO) will present additional Phase 3 CALIBRATE evidence on encaleret at the ASBMR annual meeting on October 9–12, 2026.
The meeting in Boston will include 24-week findings on patient-reported symptoms, treatment experience and bone turnover in autosomal dominant hypocalcemia type 1 (ADH1), a genetic condition affecting calcium regulation. The encaleret oral presentations are scheduled for October 11. Posters will cover baseline symptoms and daily functioning, plus findings from regional family genetic-testing events conducted with the HypoPARAthyroidism Association. Those events evaluated a model offering no-cost testing and counseling to at-risk relatives in their home region. An October 11 poster will address peripheral FGFR1 inhibition at clinically relevant infigratinib exposures and its relationship to observed safety in children with achondroplasia.
BridgeBio Pharma (Nasdaq: BBIO) will present acoramidis research at the HFSA Annual Scientific Meeting on October 9–12, 2026. The Phoenix, Arizona meeting will feature one oral presentation, three rapid-fire oral presentations and six posters on transthyretin amyloid cardiomyopathy, a condition affecting the heart.
Topics include a real-world comparison of acoramidis and tafamidis using the Epic COSMOS data platform, hospitalization and mortality, and long-term effects on cardiac function. The announcement provides presentation titles and schedules, but no numerical study results.
BridgeBio Pharma (BBIO) announced a nationwide education effort with community partners to raise awareness of transthyretin amyloid cardiomyopathy, or ATTR-CM. The condition involves protein buildup in the heart that makes it harder to pump blood. Programming begins with an October 6 YouTube premiere and continues through community conversations ahead of World Amyloidosis Day on October 26.
Sway Calloway moderates the premiere on Black men's heart health, featuring ATTR-CM advocate Howard "H" White, physician Albert J. Hicks III and Hip Hop Public Health founders Doug E. Fresh and Olajide Williams. Supporting organizations include the Association of Black Cardiologists, National Minority Quality Forum, 100 Black Men of the Bay Area and National Medical Association.
BridgeBio (BBIO) received FDA acceptance and Priority Review for its application seeking approval of oral infigratinib for children with achondroplasia. The FDA set a February 4, 2027 target action date. BridgeBio anticipates a U.S. launch upon approval and intends to submit a European marketing application in the fourth quarter of 2026.
The Phase 3 PROPEL 3 trial met its primary endpoint measuring change in annualized height velocity at Week 52: the adjusted treatment difference was +1.74 cm/year, and the mean treatment difference was +2.10 cm/year (p<0.0001). The height Z-score secondary endpoint also met statistical significance. Exploratory results included improved body proportionality in younger children and favorable trends versus placebo in sleep apnea and ear infection events. There were no discontinuations or serious adverse events related to study drug.